Plasma 25-hydroxyvitamin D and prostate cancer risk: The Multiethnic Cohort

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 932-936

  Park, Song Yi ^a   Cooney, Robert V ^a   Wilkens, Lynne R ^a   Murphy, Suzanne P ^a   Henderson, Brian E ^b   Kolonel, Laurence N ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

25 Hydroxyvitamin D; Multiethnic cohort; Nested case control study; Plasma; Prostate neoplasms

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; HISPANIC; HUMAN; INDIGENOUS PEOPLE; JAPANESE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; UNITED STATES; VITAMIN BLOOD LEVEL;

AGED; CALIFORNIA; CASE-CONTROL STUDIES; HAWAII; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; VITAMIN D;

EID: 77349112010     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.030     Document Type: Article

References (25)

1. Schwartz G.G., and Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10 (1990) 1307-1311
2. Hanchette C.L., and Schwartz G.G. Geographic patterns of prostate cancer mortality. Cancer 70 (1992) 2861-2869
3. Schwartz G.G., and Hanchette C.L. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 17 (2006) 1091-1101
4. Krishnan A.V., Peehl D.M., and Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88 (2003) 363-371
5. Moreno J., Krishnan A.V., and Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 97 (2005) 31-36
6. Zerwekh J.E. Blood biomarkers of vitamin D status. Am J Clin Nutr 87 (2008) 1087S-1091S
7. Ahn J., Peters U., Albanes D., et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100 (2008) 796-804
8. Faupel-Badger J.M., Diaw L., Albanes D., Virtamo J., Woodson K., and Tangrea J.A. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16 (2007) 2784-2786
9. Jacobs E.T., Giuliano A.R., Martinez M.E., Hollis B.W., Reid M.E., and Marshall J.R. Plasma levels of 25-hydroxyvitamin D,1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89-90 (2004) 533-537
10. Platz E.A., Leitzmann M.F., Hollis B.W., Willett W.C., and Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15 (2004) 255-265
11. Tuohimaa P., Tenkanen L., Ahonen M., et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108 (2004) 104-108
12. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., and Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11 (2000) 847-852
13. Nomura A.M., Stemmermann G.N., Lee J., et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9 (1998) 425-432
14. Gann P.H., Ma J., Hennekens C.H., Hollis B.W., Haddad J.G., and Stampfer M.J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5 (1996) 121-126
15. Braun M.M., Helzlsouer K.J., Hollis B.W., and Comstock G.W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6 (1995) 235-239
16. Corder E.H., Guess H.A., Hulka B.S., et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2 (1993) 467-472
17. International Agency for Research on Cancer. Vitamin D and cancer. IARC Working Group Reports, vol. 5. Lyon: International Agency for Research on Cancer; 2008.
18. Harris S.S., and Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 67 (1998) 1232-1236
19. Kolonel L.N., Henderson B.E., Hankin J.H., et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151 (2000) 346-357
20. Park S.Y., Wilkens L.R., Henning S.M., et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control 20 (2009) 211-223
21. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281
22. Travis R.C., Crowe F.L., Allen N.E., et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169 (2009) 1223-1232
23. Mikhak B., Hunter D.J., Spiegelman D., Platz E.A., Hollis B.W., and Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67 (2007) 911-923
24. Looker A.C., Pfeiffer C.M., Lacher D.A., Schleicher R.L., Picciano M.F., and Yetley E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 88 (2008) 1519-1527
25. Yetley E.A. Assessing the vitamin D status of the US population. Am J Clin Nutr 88 (2008) 558S-564S